Regeneron Pharmaceuticals, Inc.
MODIFIED DOSAGE OF SUBCUTANEOUS TOCILIZUMAB FOR RHEUMATOID ARTHRITIS

Last updated:

Abstract:

The present disclosure relates the dosage modification and choice of an IL6 antibody for the treatment of rheumatoid arthritis in subjects.

Status:
Application
Type:

Utility

Filling date:

11 Jun 2020

Issue date:

4 Aug 2022